Zevenbergen Capital Investments LLC Takes $32.14 Million Position in Insulet Corporation $PODD

Zevenbergen Capital Investments LLC purchased a new stake in Insulet Corporation (NASDAQ:PODD) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 113,083 shares of the medical instruments supplier’s stock, valued at approximately $32,143,000.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Brookstone Capital Management grew its position in shares of Insulet by 4.1% during the 4th quarter. Brookstone Capital Management now owns 2,511 shares of the medical instruments supplier’s stock worth $714,000 after purchasing an additional 100 shares in the last quarter. Paladin Wealth LLC raised its position in shares of Insulet by 5.9% in the fourth quarter. Paladin Wealth LLC now owns 1,888 shares of the medical instruments supplier’s stock valued at $537,000 after buying an additional 105 shares in the last quarter. J. Safra Sarasin Holding AG bought a new stake in shares of Insulet in the fourth quarter valued at approximately $2,124,000. Mn Services Vermogensbeheer B.V. grew its position in Insulet by 1.4% during the fourth quarter. Mn Services Vermogensbeheer B.V. now owns 26,968 shares of the medical instruments supplier’s stock worth $7,665,000 after buying an additional 368 shares in the last quarter. Finally, Spire Wealth Management grew its position in Insulet by 508.6% during the fourth quarter. Spire Wealth Management now owns 353 shares of the medical instruments supplier’s stock worth $100,000 after buying an additional 295 shares in the last quarter.

Insider Buying and Selling at Insulet

In related news, Director Michael R. Minogue purchased 2,030 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were bought at an average cost of $246.23 per share, with a total value of $499,846.90. Following the acquisition, the director owned 17,483 shares of the company’s stock, valued at $4,304,839.09. This trade represents a 13.14% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 0.39% of the company’s stock.

Insulet Trading Down 0.1%

Shares of PODD opened at $208.01 on Tuesday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.15 and a current ratio of 2.81. Insulet Corporation has a 52-week low of $205.11 and a 52-week high of $354.88. The firm has a market cap of $14.64 billion, a price-to-earnings ratio of 59.43, a PEG ratio of 1.25 and a beta of 1.42. The business’s fifty day moving average is $244.14 and its 200-day moving average is $287.40.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share for the quarter, topping the consensus estimate of $1.48 by $0.07. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The business had revenue of $783.80 million during the quarter, compared to the consensus estimate of $768.31 million. During the same period in the prior year, the company earned $1.15 EPS. Insulet’s revenue for the quarter was up 31.2% on a year-over-year basis. Equities analysts anticipate that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Insulet in a report on Thursday, January 22nd. Sanford C. Bernstein decreased their price target on Insulet from $380.00 to $330.00 and set an “outperform” rating on the stock in a research report on Thursday, February 19th. JPMorgan Chase & Co. dropped their price target on Insulet from $415.00 to $340.00 and set an “overweight” rating for the company in a research note on Thursday, February 19th. Citigroup reduced their price objective on shares of Insulet from $345.00 to $338.00 and set a “buy” rating on the stock in a research note on Wednesday, March 11th. Finally, Evercore set a $340.00 target price on shares of Insulet in a report on Thursday, February 19th. Twenty investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $354.24.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.